German industry demands change in health policy direction
This article was originally published in Clinica
The German industry association, BVMed, has written to the minister of health, Ulla Schmidt requesting a meeting with senior ministry officials. The association is keen to push its view that the German income-driven health system should be transformed into one in which healthcare provision has priority.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.